An en banc US Court of Appeals for the Federal Circuit said yesterday that two patents owned by The Medicines Company (MedCo) are valid in a case setting the rules for ‘on-sale’ product-by process patents.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
MedCo, Hospira, Federal Circuit, Angiomax, bivalirudin, patent, on-sale patent bar